The use of HBsAg-positive organ donors: Far more than meets the eye?

Liver Transplantation

Volumn 11, Issue 8, 2005, Pages 875-877

  Perrillo, Robert P ^a   Eason, James D ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; VIRUS DNA;

COMORBIDITY; DELTA AGENT HEPATITIS; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONOR; ORGAN DONOR; PRIORITY JOURNAL; SUPERINFECTION; VIRUS CARCINOGENESIS; VIRUS CARRIER; VIRUS REPLICATION;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HEPATITIS D; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; TISSUE DONORS;

EID: 23744488529     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20449     Document Type: Editorial

References (16)

1. Fuster J, Charco R, Llovet JM, Bruix J, Garcia-Valdercasas JC. Liver transplantation in hepatocellular carcinoma. Transpl Int 2005;18:278-282.
2. Loss GE, Mason AL, Nair S, Blazek J, Farr G, Cohen AJ, et al. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl 2003;9:1258-1264.
3. Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for antihepatitis B - core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003;75:1179-1186.
4. Szmuness W, Hoofnagle JH, Stevens CE, Prince AM. Antibody against the hepatitis type B core antigen. A new tool for epidemiologic studies. Am J Epidemiol 1976;104:256-262.
5. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337: 1733-1745.
6. Gonzalez-Peralta RP, Andres JM, Tung FY, Fang JW, Brunson ME, Davis GL, et al. Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus-negative recipient. Transplantation 1994;58:114-116.
7. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - Summary of a workshop. Gastroenterology 2001; 120:1828-1853.
8. Ottobrelli A, Marzano A, Smedile A, Recchia S, Salizzoni M, Cornu C, et al. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology 1991;101: 1649-1655.
9. Franchello A, Ghisetti V, Marzano A, Salizzoni M. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and role of hepatitis delta coinfection. Liver Transpl 2005;11:922-928.
10. Smedile A, Casey JL, Cote PJ, Durazzo M, Lavezzo B, Purcell RH, et al. Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope. Hepatology 1998;27: 1723-1729.
11. Lau DT, Doo E, Park Y, Kleiner DE, Schmid P, Kuhns MC, et al. Lamivudine for chronic delta hepatitis. Hepatology 1999;30: 546-549.
12. Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995;109:908-916.
13. Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004;24(suppl 1):55-62.
14. Schilling R, Ijaz S, Davidoff M, Lee JY, Locarnini S, Williams R, et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B surface antigen and virions. J Virol 2003;77:8882-8892.
15. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003;39 (suppl 1):S64-S69.
16. Nair SN, Perrillo RP. Hepatitis B and D. In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease. Vol. 2. 4th ed. Philadelphia: Saunders; 2003:959-1016.